0512-8957 3668 / 18013764755
Agonists of prostaglandin E 2 receptors as potential first in class treatment for nephronophthisis and related ciliopathies
来源: | 作者:Hugo Garcia 1 2, Alice S Serafin 1, Flora Silbermann 1, Esther Porée 1, Amandine Viau 1, Clémentine Mahaut 3, Katy Billot 1, Éléonore Birgy 1, Meriem Garfa-Traore 1, Stéphanie Roy 1, Salomé Ceccarelli 1, Manon Mehraz 1, Pamela C Rodriguez 3, Bérangère Del | 发布时间: 2022-05-14 | 96 次浏览 | 分享到:

SignificanceJuvenile nephronophthisis (NPH) is a renal ciliopathy due to a dysfunction of primary cilia for which no curative treatment is available. This paper describes the identification of agonists of prostaglandin E2 receptors as a potential therapeutic approach for the most common NPHP1-associated ciliopathies. We demonstrated that prostaglandin E1 rescues defective ciliogenesis and ciliary composition in NPHP1 patient urine-derived renal tubular cells and improves ciliary and kidney phenotypes in our NPH zebrafish and Nphp1-/- mouse models. In addition, Taprenepag alleviates the severe retinopathy observed in Nphp1-/- mice. Finally, transcriptomic analyses pointed out several pathways downstream the prostaglandin receptors as cell cycle progression, extracellular matrix, or actin cytoskeleton organization. Altogether, our findings provide an alternative for treatment of NPH.

Keywords: drug-screen; kidney; nephronophthisis; primary cilia; prostaglandins.

原文地址:http://www.ncbi.nlm.nih.gov/pubmed/35482924